A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

Pivoting to GLP-1 RAs, Soung explained that they both decrease appetite and food cravings and are very different from the weight loss drugs of the past in terms of how they work, the fact that they ...

Discover a study on psoriasis treatment failure, highlighting when to move from topical therapies to systemic care for ...

A recent Phase 3 clinical trial demonstrated that a steroid-free topical foam, roflumilast (Zoryve), significantly improved the signs and symptoms of psoriasis on both the scalp and body. The foam ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, announces ...

Genital psoriasis is common in psoriasis patients and shouldn't cause shame or interfere with your sex life, says ...

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...